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  The FDA antiviral drug, Tamiflu (oseltamivir) is the front-line antiviral drug for 
the fight against 2003 avian flu (H5N1) as well as, more recently, for the 2009 swine flu 
(H1N1pdm). The drug functions as a neuraminidase inhibitor that prevents the release of 
new virions. Unfortunately, there is emerging evidence that the neuraminidase mutations 
H274Y and N294S render oseltamivir ineffective against the H5N1 virus.  Of greater 
concern is the growing likelihood of the emergence of similar oseltamivir-resistant strains 
of H1N1pdm. It is therefore critical to understand the mechanisms for mutation-induced 
drug resistance in the H5N1 and H1N1pdm flu viruses in order to develop new and 
effective therapies.  As molecular dynamics (MD) simulations have become an important 
tool for the study of biological systems, this dissertation aims to employ MD simulations 
for computer-aided rational drug design. Specifically, different MD simulation techniques 
were utilized in the investigation of oseltamivir-resistant mechanisms of 
H5N1/H1N1pdm and for the development of new antiviral drugs. 
 Chapter 1 is simply a general introduction to the whole thesis. Chapter 2 presents 
top-hits for H1N1pdm neuraminidase identified by virtual screening using ensemble-
based docking technique, which incorporates protein flexibility into molecular docking. 
 iv 
Next in Chapter 3, progress in the development of two related methodologies for 
calculation of solvation free energy, one called the Coupled Reference Interaction Site 
model-hyper-netted chain/molecular dynamics (RISM/MD) approach, and another called  
Molecular Mechanics Poisson−Boltzmann linear response approximation and surface 
area contributions (MMPB-LRA-SA), are presented.  The methods are expected to be 
applicable to the lead refinement process since they provide more reliable results than the 
continuum model but are less computationally expensive than conventional MD methods. 
In Chapter 4, we discuss our observations based on drug-protein endpoint interactions on 
how the mutations H274Y and N294S induce oseltamivir resistance in neuraminidase N1 
subtypes. However, since the two mutations are non-active-site, endpoint interactions 
alone cannot fully account for the drug resistance. In Chapter 5, we present our finding of 
the drug binding pathway through electrostatic surface potential and steered MD 
simulation. The results reveal a novel oseltamivir-resistant mechanism in which the 
mutations rupture the drug binding funnel, in conjuction with the findings reported in 
Chapter 4. Our study not only assists understanding of oseltamivir-resistance in 
neuraminidase N1 subtypes, but also bears several important consequences for the 
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 Nowadays, information needed for computer-aided drug design can be accessed 
easily. There are more than 64,000 coordinate entries of macromolecules revealed by X-
ray, NMR, and Electron Microscopy techniques available in the Brookhaven Protein Data 
Bank
1
. Many new target proteins whose 3D structures have not been solved 
experimentally can still be easily predicted by homology modeling with adequate 
reliability. Similarly, thousands of compounds including their drug-like properties are 




 and the Drug 
Bank
4
. Therefore, it is crucial to develop suitable tools to take advantages of these 
promising resources for rational drug design. MD simulation has proven itself as a 
complement to lab experiments to fill in the gaps in our knowledge between 3D 
structures of biological targets and their potential inhibitors.
5
  
 In the fight against influenza A viruses, which have killed millions of human 
being throughout history, it is important to utilize MD simulations to speed up the 
rational design of antiviral drugs. Due to their ability to mutate quickly, the viruses can 
easily survive people’s immune systems and resist current drugs.  Drug resistance5 




spite of being given oseltamivir.
6
 Currently, there are two pathogenic viruses,  the 2003 
avian flu (H5N1)
7
 virus and recently the 2009 swine flu (H1N1pdm)
8
 virus, which share 
the same subtype 1 (N1) of neuraminidase. Neuraminidase, a glycoprotein component on 
a flu virus’ surface that cleaves the alpha-ketosidic linkage of sialic acid (SA) located on 
human cells to release new virions that then infect nearby healthy cells, is the most 
important target for antiviral drug design.
9
 Oseltamivir functions as a neuraminidase 
inhibitor that binds competitively to the SA binding site of the neuraminidase. The 
presence of oseltamivir prevent the release of new virions, as shown in Figure 1.1. In this 
dissertation, different MD simulation techniques
10, 11
 are applied to investigation of the 
oseltamivir-resistant mechanism and to rational drug design targeting neuraminidase N1 
subtypes. 
 
Figure 1.1 Oseltamivir functions as a neuraminidase inhibitor, preventing the release of 




In the lead discovery stage, thousands of compounds from free chemical 
databases are docked against the rigid structures of receptors. Such screening processes 
are fast but are associated with a high number of false positives and false negatives. 
Flexible docking has improved the outcome of this process, but to a very limited degree. 
A recent method that significantly increases the accuracy of the lead identification 
process is called ensemble-based docking.
12
  This method combines the docking 
algorithm with the dynamic structure of proteins taken from MD simulations as well as 
statistical analysis of binding energy. Chapter 2 presents top-hits for H1N1pdm 
neuraminidase identified by virtual screening using the ensemble-based docking 
technique.
13
 The molecular model of H1N1pdm used in the docking experiment was built 




 The next step in drug development after screening is how to distinguish among 
equally well bound hits. In lead optimization, accurate calculation of ligand binding 
affinity is crucial. In most computational methods solvation components and 
intramolecular components are computed separately and summed to yield the total free 
energy.  A typical mammalian cell consists of more than 85% water, and so most 
biochemical processes modeled must be treated within an aqueous environment and 
solvation free energies need to be taken into account. Commonly used solvation free 
energy methodologies include the computationally inexpensive continuum solvation 
models, which unfortunately do not always lead to reliable results; and molecular 
simulation methods, such as thermodynamic integration and thermodynamic perturbation, 




In Chapter 3, the  new methodologies for calculation of solvation free energy called 
coupled reference interaction site model-hyper-netted chain (RISM-HNC)/MD
15
 and 
molecular mechanics Poisson−Boltzmann/ linear response approximation and surface 
area contributions (MM-PB/LRA-SA)
16
 developed by Freedman et al. are presented. The 
authors aim to develop methods that yield more reliable results than continuum models 
but are less computationally expensive than conventional MD methods. The methods 
have obtained very positive preliminary results and are still under development for 
application in drug design. 
 Another important aspect of rational drug design is to understand all drug-protein 
interactions at an atomistic level and how these interactions are ruptured by certain 
mutations, leading to drug resistance. Thorough understanding of drug resistant 
mechanisms is crucial for the design of new agents effective against current drug-
resistant strains. To understand how mutations H274Y and N294S induce oseltamivir 
resistance in neuraminidase N1 subtype, analysis of the drug binding was studied 
thoroughly by equilibrium MD simulations.  We have observed important hydrogen bond 
and hydrophobic interactions between the protein and drug that can not be seen in static 
crystal structures. The results discussed in Chapter 4 identify important potential sources 
of oseltamivir resistance, mainly the loss of hydrogen bonds with R152 and hydrophobic 
interaction of oseltamivir’s bulky pentyl group in the case of mutant H274Y. This leads 
to our suggestion to replace the pentyl group by a more hydrophilic one by adding a few 
hydroxyl groups onto the drug. Since the two mutations are non-active-site, endpoint 
interactions alone cannot fully explain the drug resistance mechanism. Sources of drug 




calculations from equilibrium (EQ) simulations reveal  both residues 274 and 294 located 
on a distinct negatively charged column of residues, that can lead to another drug 
resistance mechanism.  
 In Chapter 5, we discuss our finding of the drug binding pathway through 
electrostatic surface potential and steered MD (SMD) simulation.
17
 The findings were 
then validated by 10 subsequenced EQ simulations (EQ simulations with starting 
structure taken from SMD simulation). More importantly, mutation H274Y and N294S 
were found to be located on or adjacent to the binding funnel. The results reveal a novel 
oseltamivir-resistant mechanism, in which the mutations rupture the drug binding funnel, 
complementary to what is reported in Chapter 4.  The findings in Chapter 4 are important 
for the rational design of a drug with good binding kinetics. It poses the question of 
whether similar binding funnels exist in other types of neuraminidases. The mutations 
affect binding of oseltamivir but certainly not its natural substrate SA. Another FDA 
antiviral drug, zanamivir (Relenza)
18
 might enter the binding pocket in a similar way as 
SA does, leading to insensitivity to these two mutations. 
 Our study has provided insights into the oseltamivir-resistant mechanism and 
suggestions for further studies involving other commercial drugs, other subtypes of 
neuraminidase as well as intelligent design of new antiviral drugs that work for 
established drug-resistant variants. As oseltamivir resistance is emerging, the 
development of new neuraminidase inhibitors and other drug classes (e.g. M2 channel 









 CHAPTER 2  
 
PROMISING ANTIVIRAL DRUGS FOR SWINE FLU  
H1N1PDM REVEALED BY VIRTUAL SCREENING  
USING ENSEMBLE-BASED DOCKING 
 
 
Here we describe how top-binding compounds to the swine flu H1N1pdm were 
identified by the ensemble-based docking technique. This work is in collaboration with 
Hung Nguyen. My contribution was preparing ligands and the receptor for docking, 
repeating some docking procedures for validation, making some figures and writing part 
of the manuscript. 
 
2.1 Receptor 
2.1.1 Molecular model of H1N1dpm neuraminidase 
The atomic structure of H1N1pdm neuraminidase is not known.  However, the 
fact that the H1N1pdm strain responds positively to oseltamivir which is effective against 
H5N1, suggests similarities to H5N1 neuraminidase. The amino acid sequence of 
H1N1pdm neuraminidase was obtained from Genbank Locus ID CY041156 and that of 
H5N1 neuraminidase from the Protein Data Bank (PDB entry 2HU4).
19
 Sequence 
alignment performed using Multiseq in VMD
20
 shows that H1N1pdm has a higher 
percentage sequence identity (91.47 %) with H5N1 excluding the transmembrane and 




counterparts in the Americas.  At the drug binding pocket, the notable difference between 
H1N1pdm and H5N1 neuraminidase is the replacement of Y347 by N347.
14
 
H5N1 neuraminidase was used as a template to build a homology model of H1N1pdm 
neuraminidase by Modeller9v7
21
 and a molecular model of H1N1pdm by mutating the 
corresponding residues in H5N1 to match the wild type H1N1pdm using a home-made 
script in VMD. Both the homology and molecular model of swine H1N1pdm have also 
revealed high similarity to template, in discrete optimized protein energy (DOPE) per-
residue score, shown in Figure 2.1. As DOPE is the most  important factor to validate the 
quality of  built 3D models,
22
 the results indicate that the 3D structure of both the 
homology and molecular models are highly similar to the 3D model of the template. 
 
 
Figure 2.1 Discrete optimized protein energy (DOPE) per-residue of homology and 
molecular model of H1N1pdm neuraminidase in comparison with that of template avian 





In order to easily retain the coordinates of oseltamivir, the crystallographically 
resolved water molecules, and a structurally relevant calcium ion near the native binding 
site for SA in the template, the molecular model was used for further study.  The protein 
complexes were then solvated in a TIP3P
23
 water box and ionized by NaCl (0.152M) to 
mimic physiological conditions.  The solvated H1N1pdm system with bound oseltamivir 
is shown in Figure 2.2A, with schematic views of the buried drug in the SA binding site 
shown in Figure 2.2B. 
Simulation parameters for oseltamivir were developed within the CHARMM 
force field
24





Figure 2.2 Schematic representations of drug-bound simulation systems. Shown here as a 
representative example of simulated systems is H1N1pdm bound to oselvamivir. In A), 
the simulation system is shown in the full explicit solvation box with oseltamivir and the 
active-site calcium ion labeled. In B), oseltamivir is shown buried in the SA binding 






with the CMAP correction.
25
 Parameters for ligands were prepared using Paratool
26
 in 
VMD. Structure optimization and frequency calculations were performed at the level of 
HF/6-31G* by Gaussian03
27
 and subsequently imported into Paratool. Atom types and 
charges already described in an existing CHARMM force field were assigned using those 
existing parameters;  however, the atomic charges for the atoms in oseltamivir’s six 
member ring were newly parameterized by dividing the ring into several small fragments, 
and atomic charges for the six-member ring atoms recalculated based on the total charge 
of each fragment. Fragments not explicitly defined in the CHARMM force field were 
modeled using analogs in CHARMM force field extensions which fit closely to the 
fragment being parameterized. The dihedral angle potentials, which render the respective 
torsions highly rigid due to electron delocalizations, were generated from the quantum 
mechanical calculations.   
 
2.1.2 MD simulation of ionized oseltamivir-neuraminidase complex 
All simulations were performed using NAMD 2.7
20
 and the CHARMM31 force 
field with the CMAP correction.  The ionized systems were minimized for 10,000 
integration steps and equilibrated for 20 ns with a 1 fs time step. Following this, a 20 ns 
unconstrained equilibration production run was performed for subsequent trajectory 
analysis, with frames stored after each picosecond (every 1000 time steps).  Constant 
temperature (T = 300 K) was enforced using Langevin dynamics with a damping 
coefficient of 1 ps
−1
.  Constant pressure (p = 1 atm) was enforced using the Nosé-Hoover 
Langevin piston method. Van der Waals interaction cutoff distances were set at 12 Å 




computed using the particle-mesh Ewald (PME) summation method.  The trajectories 
from our 20ns production run of EQ simulation of H1N1pdm neuraminidase with 
oseltamivir bound, were clustered as shown in Figure 2.3, and then used for ensemble-
based docking.  
 
2.1.3 RMSD clustering to extract receptor ensembles from an all-atom  
MD simulation 
The holo system with oseltamivir  removed was used for RMSD clustering and 
the docking experiments. Clustering analyses were performed on 20 ns MD trajectories 
using the g_cluster tool in the Gromacs package.
28
  In brief, snapshots at every 10 ps over 
 
 
Figure 2.3 13 representative ensembles resulting from clustering analysis, accounting for 
96.2% of the configuration space, are ordered by the corresponding simulation time. The 
four largest cluster ensembles account for over 66% of the configuration space from the 






the 20 ns simulation were recorded. 2000 resulting structures were superimposed, using 
all Cα atoms to remove possible rotational and translational movements of the whole 
system. We have visually verified that the binding-site residues of avian H5N1 
neuraminidase, which cover the active site and are responsible for interaction with 
putative inhibitors, can also be used for the swine flu H1N1pdm neuraminidase. The four 
most populated clusters is shown in Figure 2.4. 
The RMSD clustering analysis was performed on this subset (117-119, 133-138, 
146-152, 156, 179, 180, 196-200, 223-228, 243-247, 277, 278, 293, 295, 344-347, 368, 
401, 402, and 426-441) using all-atoms (including side chains and hydrogen atoms) with  
 
Figure 2.4 Overlapping structures of the four most populated clusters. The most 
dominant cluster is colored in orange, the second one in silver, the third one in blue and 




the cutoff  of 1.5 Å. A total of 13 representative clusters were obtained, which account 
for 96.2% of the configuration space from the 20 ns MD trajectories. These 13 clusters 
were used in the docking experiments.  
 
2.2 Ligands 
The high percentage sequence identity (91.47 %) of swine H1N1pdm compared to 
avian H5N1 neuraminidase, and similarities in 3D structures (active-site 150-loop and SA 
binding site residues) explain why oseltamivir, which has been developed for the H5N1 
virus, is also effective against the swine flu virus H1N1pdm. These facts also suggest that 
top-binding ligands of avian H5N1 are likely to have high affinity to the swine flu 
H1N1pdm neuraminidase. Therefore the 27 top hits for H5N1 neuraminidase, suggested 
by Cheng et al.
7 
from performing full virtual screening on H5N1 neuraminidase using the 
diversity set from the National Cancer Institute (NCI) small molecule database, were 
used in our study.  
In this study, 32 ligands were used as a starting point for searching for promising 
antiviral drugs against the H1N1pdm neuraminidase, using the ensemble-based docking 
approach. The ligand set includes the 27 top-hit compounds from Cheng et al. and six 
additional compounds for reference purpose, namely: SA, N-acetyl neuraminic acid, aka, 
NANA or Neu5Ac), DANA (2,3-didehydro-2-deoxy-N-acetyl neuraminic acid), 
oseltamivir, zanamivir , peramivir (clinical trial phase 3 drug candidate)  and SK 
(shikimic acid, widely used as a chiral building block in the synthesis of oseltamivir). 
Ligand structures were obtained from the NCI and optimized by the MOPAC module 





2.3 Molecular docking  
In the docking experiments, the 13 most representative configurations were used 
as receptors. AutoDockTools 1.5.2
 
was used to add polar hydrogens, assign Gasteiger 
charges
11
 and create grid binding boxes. The volume of each grid box was 72 x 72 x 72, 
with the default 0.375 Å spacing.  The binding box was positioned to encompass all three 
possible binding sites, namely the SA, 150 and 430 cavities. AutoGrid version 4.2.1 was 
used to calculate the binding affinities using the following atom types: A (aromatic 
carbon), C, N, NA (hydrogen bond accepting N), OA (hydrogen bond accepting O), P, S, 
SA (hydrogen bond accepting S), Cl, HD (polar hydrogen) and e (electrostatics). 
  AutoDockTools version 1.5.2 was also used to merge nonpolar hydrogens, add 
Gasteiger charges and visually set up rotatable bonds for each ligand via AutoTors. The 
Lamarckian genetic algorithm was used to do the docking experiments using AutoDock 
4.2.1.
16
   Docking parameters were chosen to reproduce structures of 13 corresponding 
oseltamivir–neuraminidase complexes in the MD simulation. Other parameters are as 
follows: trials of 100 dockings, population size of 200, random starting position and 
conformation, translation step range of 2.0 Å, rotation step range of 50 degrees, 
maximum number of generations of 27000, elitism of 1, mutation rate of 2%, crossover 
rate of 80%, local search rate of 6%, 8 million energy evaluations, unbound model was 





Docking results were sorted by the lowest binding energy of the most populated 
cluster in cases of convergence. In the case of no dominant cluster, docking results were 
visually analyzed using VMD to choose the best binding pose. 
 Hydrogen bond analysis utilized a distance and angle cutoff of 3.5 Å and 45 
degrees, respectively. The appearance frequency (AF) of important hydrogen bonds is 














=AF     (2.1) 
 
where i is the index number of each ensemble; ni the size of each ensemble; and hi = 1 if 
hydrogen bond exists, and 0 otherwise. 
After the dockings, statistical calculations were performed to obtain the final 
binding energies for compound ranking, using the arithmetic mean (AM) and harmonic 
mean (HM) binding energies as defined in the previous study.    
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SD                                                    (2.3) 
 
The harmonic means were calculated by first converting the binding energies into 







         (2.4) 
where R is the Boltzmann constant and T is the temperature (298.15K) 



















      (2.5) 
then the calculated iK were converted back to HM binding energies. 
 
 
2.4. Results and discussion 
2.4.1 Comparing binding modes of oseltamivir from molecular  
docking and MD simulation 
First, we compared the binding modes of oseltamivir to the H1N1pdm 
neuraminidase resulting from the present docking experiment, to those from the previous 





suggested by McCammon and co-workers, 
29-31
 docking results are in good agreement 
with those from the MD simulation for oseltamivir.  As shown in Figure 2.5, the two 
average structures are nearly superimposed except for the pentyl group. Also shown are 
residues, which frequently interact with oseltamivir via hydrogen bonds: E119, D151, 
R292, and R371. One main reason that its binding free energy is less than that in the 
H5N1 case, as discussed below, is the loss of contact with R118. 
As shown in Table 2.1, the maximum all-atom RMSD between the two docking 
and MD ligand binding poses is less than 2 Å, and the average RMSD is of only 1.5 Å. 
The difference between the binding poses lies mainly in the orientation of the pentyl 
ether group, which interacts with the receptor primarily via hydrophobic forces. When 
excluding this group from the analysis, the average RMSD drops to below 1.1 Å.   
 
 
Figure 2.5 Oseltamivir docked in SA cavity of H1N1pdm neuraminidase as compared to 










Table 2.1 RMSD of the binding structures of oseltamivir  from docking results in the 13 
receptor ensembles compared to those extracted from the 20ns MD simulation. Also 
listed are the percent of population of the receptor ensemble, the percent contribution of 















ligand cluster  
1 22.65 1.21 1.21 96 
2 18.70 1.41 0.63 81 
3 10.20 1.74 1.17 73 
4 9.45 1.95 1.37 65 
5 8.40 1.74 1.04 83 
6 7.00 1.20 1.17 88 
7 5.20 1.80 1.20 66 
8 3.20 1.11 1.15 89 
9 3.10 1.13 0.56 72 
10 2.30 1.77 0.90 69 
11 2.25 1.81 1.17 61 
12 1.90 1.55 1.54 74 
13 1.50 1.16 1.13 58 
Mean 
Non-weighted 1.51 1.10 
 









This comparison validates the accuracy of the ensemble-based docking approach. 
Docking results over 13 receptor ensembles also show consistent statistics with the most 
populated cluster having the lowest binding energy and the largest percent population of 
the ligand cluster is found in the ensemble with largest percent population in the receptor 
space (see ensemble 1 as compared to ensemble 13). 
 
2.4.2. Ranking of the top binding compounds 
The ranking is made according to the harmonic mean of binding free energy 
instead of the arithmetic mean, since it gives more weight to the more populated clusters. 
The better performance of the harmonic mean of binding free energy, shown in Figure 
2.6, is also seen in previous studies.
32, 33
 
First, differences in the present ranking results for these top hits against 
H1N1pdm from those reported in the previous study for the avian  H5N1 neuraminidase 
were observed. As shown in Table 2.2, some compounds rise (2, 5 and 6 as compared to 
the ranks of 16, 20 and 14, respectively for H5N1) while others move down (29, 19 and 
25 as compared to 6, 3 and 9, respectively) in the ranking list.  Oseltamivir retains its 
relatively high rank (with new/old rank of 7/4) while the changes in the rank for 
paramivir and zanamivir are substantial (peramivir jumps from 26 to 8, right after 
oseltamivir, and zanamivir falls from 5 to 26). Still, there are compounds such as 1, 3, 10 








Figure 2.6 Binding energies of 33 compounds are listed with their NSC ID. Minimum 
energy is the lowest binding free energy docking into all 13 receptor ensembles.  HM and 





There are two possible reasons for the observed differences in the ranking order 
for the top hits calculated here for H1N1pdm as compared to those in the study for H5N1.  
One is the differences in the hydrogen-bond networks in the H1N1pdm and H5N1 
systems, as discussed in more detail below, and another may be due to the improvement 
in the free energy scoring function in AutoDock 4.2.1.
34
   It is important to point out that 
the current approach may misidentify candidates in the NCI diversity set that should be in 
the top candidate list. Since the binding cavities of H1N1pdm and H5N1 are very similar, 
the number of such candidates should be rather small.  However, to identity such 








Table 2.2 Docking results for 33 compounds ranked by harmonic mean of binding 
energy. The first column is the final rank and also the compound ID.  The predicted Ki 
calculated according to the harmonic mean binding free energies are also shown, as well 




























































































1 2 211332 -12.05 0.001 -11.73 0.61 
 
2 16 141562 -10.14 0.037 -9.87 0.63 
 
3 1 109836 -9.74 0.072 -9.50 0.47 
 

































































































5 20 164640 -8.95 0.274 -8.78 0.42 
 
6 14 5069 -8.85 0.326 -8.23 1.11 
 

































































































8 26 Peramivir -8.47 0.615 -8.38 0.36 
 
9 17 117079 -8.46 0.633 -7.70 0.98 
 

































































































11 21 135371 -8.36 0.745 -8.08 0.55 
 
12 27 70194 -8.26 0.882 -7.89 0.88 
 
































































































14 30 371688 -8.15 1.067 -6.75 1.15 
 
15 25 59620 -8.07 1.220 -7.50 0.82 
 
16 7 17245 -8.07 1.223 -7.85 0.54 
 
17 15 327705 -8.04 1.273 -7.69 0.57 
 
25 


























































































18 11 37245 -7.96 1.454 -7.92 0.24 
 
19 3 45583 -7.69 2.292 -7.21 0.75 
 

































































































21 23 46080 -7.51 3.110 -7.04 0.69 
 
22 28 18312 -7.46 3.376 -6.91 0.79 
 






































































































24 18 327704 -7.27 4.700 -7.05 0.53 
 
25 9 148354 -7.19 5.381 -7.07 0.39 
 
26 5 Zanamivir -7.12 6.056 -6.72 0.78 
 

































































































28 12 45582 -6.88 8.980 -6.71 0.43 
 
29 6 106920 -6.57 15.338 -6.16 0.66 
 
30 32 16163 -6.12 32.802 -5.84 0.55 
 






























































































































Figure 2.7 shows the binding energy spectra of the three known bird flu drugs, 
zanamivir, oseltamivir and peramivir along the MD simulation time of H1N1pdm.  
Specifically it is the plot of the binding energies of these ligands with each of the 
H1N1pdm cluster ensembles.  The results show zanamivir as consistently having a 
smaller binding energy compared to the other two drugs.  A particularly interesting result 
here is the prediction of zanamivir to be much less effective against H1N1pdm than 
peramivir, whereas the previous study predicted that it is more effective for treating 
H5N1. The present calculated result confirms the observed effectiveness of oseltamivir 
for treating both H1N1pdm and H5N1.  This confirmation not only provides another 
validation of the accuracy of the ensemble-based docking approach used in this study but 
also demonstrates the capability of the virtual screening technique in general. 
 
 






2.4.3. Hydrogen bond analysis of top binding compounds 
Consistent with results from the recent MD simulation, docking results also show 
that oseltamivir forms strong hydrogen bonds with E119, D151, R292 and R371.  In 
particular, the amino (NH3
+
) group of oseltamivir forms strong hydrogen-bonds with the 
carboxyl (COO
-
) groups of E119 and D151, whereas its carboxyl group forms hydrogen 
bonds with the guanidinium (NHC(=NH2
+
)NH2) groups of R292 and R371.  These 
hydrogen bonds are highly conserved in all 13 receptor ensembles.  The Guanidinium 
group of R152 and the carboxyl groups of R227 and R277 sometimes form hydrogen 
bonds with the amide group of oseltamivir (Table 2.3, Figure 2.8). 
 
 
Table 2.3 The frequency of hydrogen bond (in percent) for binding site residues with 
known drugs and top binding compounds utilizing the hydrogen bond distance and angle 
cutoffs of 3.5Ǻ and 450, respectively. 
 




















E119 100 0 97 100 22 14 100 100 41 
D151 97 0 14 100 0 0 98 98 47 
R152 0 0 0 0 6 60 42 19 63 
R156 0 100 94 0 71 8 0 0 0 
W178 49 0 33 6 40 0 0 22 10 
E227 98 0 0 94 16 0 13 100 100 
E277 51 0 0 96 3 46 27 100 74 
R292 0 0 97 100 3 72 100 100 100 
R371 0 0 97 100 0 76 100 100 100 





























Peramivir and zanamivir, like oseltamivir, also form highly conserved hydrogen 
bonds with the guanidinium groups of R292 and R371 through their carboxyl groups 
(Table 2.3, Figure 2.9). Peramivir’s guanidinium group also has strong contacts via 
hydrogen bonding and electrostatic interaction with carboxyls of E119, D151, E227 and 
E277; however, zanamivir does not. Its guanidinium still makes hydrogen bonds with 
these residues, but less frequently as compared to oseltamivir and peramivir. This 
partially explains its smaller binding free energy (less negative) compared to the swine 
flu H1N1pdm neuraminidase. Another reason may be due to the receptors used in the 
docking procedure having been taken from the oseltamivir-bound holo structures, which 
possibly do not have good induced-fit effects towards zanamivir. 
Compound 1, which has a pyrimidine carbonitrile framework, binds tightly in the 
SA cavity in all 13 receptor ensembles regardless of their flexibility. This compound not 
only forms hydrogen bonds with E119 and E227 reported in a recent study on avian 
H5N1 neuraminidase,
7
 but also forms strong ones with D151, and weak ones with W178, 
E277 and Y406 (Table 2.3, Figure 2.9A). This can explain its extremely low binding 
energy and thus its high ranking. Compound 3 (Figure 2.9C), on the other hand, binds 
less effectively to H1N1pdm than H5N1 neuraminidase due to the loss of interactions 
between its nitro (NO2) and guanidinium of R118. The guanidinium groups of the three 
residues (R118, R292 and R371) in the swine flu H1N1pdm neuraminidase are not in 
close proximity like those in H5N1. Therefore, several compounds including 2, 
oseltamivir, peramivir and zanamivir lose part of their binding affinity since in H5N1 
they usually form stronger hydrogen bonds with this trio. The special case is 2, which has 






Figure 2.9 Docked structure of top-hits against swine flu neuraminidase (shown in CPK). 
A: NSC211332 (1); B: NSC141562 (2); C: NSC109836 (3); D: NSC350191 (4); E: 
NSC164640 (5);  F: NSC5069 (6). Some residues predicted to be important are also 














































guanidinium group of R156. Its binding energy is mainly due to electrostatic interactions 




Since the H1N1pdm neuraminidase primary structure is 91% similar to that of 
H5N1 and the active sites of both proteins are similar, this study used the top hit 
compounds for H5N1 as the starting point of the virtual screening process to find 
promising antiviral drugs for H1N1pdm using the ensemble-based docking technique.  
All 33 compounds, including the top binding compounds to avian H5N1 neuraminidase 
from the NCI diversity set and known drugs, were docked to ensembles of 13 H1N1pdm 
configurations that represent more than 96% of the configuration space covered by a 20 
ns MD simulation.  The results obtained reveal that 6 compounds, specifically 
NSC211332, NSC141562, NSC109836, NSC350191, NSC1644640, and NSC5069, have 
higher binding affinity to the H1N1pdm neuraminidase protein than oseltamivir does.  
The results also confirm the observed effectiveness of oseltamivir against both the swine 
H1N1pdm and H5N1 flu.  Detailed analysis on the hydrogen bond networks between top 
binding candidates with the swine H1N1pdm neuraminidase protein reveals that the 
mutations H274Y and N294S do not have any direct interactions with these compounds, 
and thus suggest the possibility of using the present top hit compounds for further 
computational and experimental studies to design new antiviral drugs against swine 
H1N1pdm flu virus and its variants.  Furthermore, a more complete virtual screening 
using the full NCI diversity set or larger sets from the ZINC database should be done to 












In Chapter 3, recent progress in development of the two new methodologies for 
solvation free energy called coupled RISM-HNC/MD and MM-PB/LRA-SA developed 
by Freedman et al., are presented. My contributions to the work here were developing 
and implementing a parallel method (using MPI – Message Passing Interface) to calculate 
radial distribution functions used as input for the two methods and running some MD 
simulations for assessment. 
 
3.1 Improving the performance of the coupled reference interaction 
 site model – hyper-netted chain (RISM-HNC) / MD  method for 
 free energy of solvation 
3.1.1 Introduction of RISM-HNC/MD 
RISM-HNC/MD
35, 36
 is an approach to calculate solvation free energy by solving 
the RISM equation as a function of radial distribution functions (RDF) taken from MD 
simulations in combination with the equation HNC as a closure relation. The idea of 
combining the RISM and HNC equations to solve for RDFs and then using these and the 
RISM equation to determine solvation free energy  has been done.
37-40
 However, by using 
  
37 
more accurate RDFs from MD simulations, the authors argue that RISM-HNC/MD will 
produce more accurate results as well as solve the convergence problems appearing if 
solving RISM for RDFs. 
 
3.1.2 Using the hard-sphere (HS) free energy as the reference and  
a linear response approximation (LRA) to improve the  
performance of the RISM-HNC/MD method 
In the prior studies by Freedman et al., the coupled RISM-HNC/MD method has 
produced reasonable relative solvation free energies for small systems. Specifically, the 
method has been employed successfully for studies of the potential of mean forcec curve 
of SN2 Cl
-
 + CH3Cl reaction in water,
41
 the conformational analysis of the alanine 
dipeptide
42
 and tautomeric equilibria of 2-Hydroxypyridine/2-Oxopyridine and of 
cytosine in water
43
 However, errors have appeared when it has been applied to larger-
sized systems. A hard-sphere reference free energy and a linear response have been 
introduced to attempt to eliminate the contribution to the solvation free energy from the 
unknown bridge function, which otherwise introduces a sizeable error in proportion to the 
solute’s size.15 This approach aims to reduce the size of the matrices in the RISM 
equation to a more manageable scale.  
Using the hard-sphere reference combined with the coupled RISM-HNC/MD, the 
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Besides HNC/HS, two other solvation free energy expressions were tested here including 
the Gaussian Fluctuation (GF) expression,
44
 the partial wave (PW) expression
45, 46
 (by 
replacing  the term 

h k  h
HS k 
2
   in equation 3.1), and finally the LRA formulation. 
 
3.1.3 Methodology assessment  
The approach using the hard-sphere reference combined with the four above-
mentioned expressions (HNC, GF, PW and LRA) was employed for solvation free energy 
calculation of several organic molecules. Freedman et al.
35
 suggested that reasonable 
predictions were obtained when they used a low-k cutoff of 1.5 for c
RISM
. In this study, 
results derived from three values of k (1.3, 1.4 and 1.5) were reported in order to obtain 
information about the numerical error associated with different cutoffs. It was seen that 
k=1.4 performs best in this study. After that, the results were compared with those from 




Results presented as follows were obtained by adding each of the variants 
HNC/HS, GF/HS, and PW/HS as well as LRA/HS to free energy of cavity formation 
terms associated with using a hard sphere potential. 
LRA/HS predicts well the solvation free energy of some small cyclic molecules, 
even better than FEP calculations in the case of phenol and cyclohexane, as shown in 
Table 3.1.  
 
Table 3.1. Free energies of solvation (kcal/mol) calculated by coupled RISM-HNC/MD 
compared to experimental values, FEP values, and stand-alone RISM-HNC results of 






























































































-7.97 -3.80 -3.7 -6.62 
 









Reasonable results were also obtained using PW/HS and GF/HS while those from 
the HNC/HS method are least accurate (markedly too positive values for all molecules). 
This approach was also validated on methylamine and N-methylacetamide 
(NMA) and the results are shown in Table 3.2. GF/HS yields values close to those of 
FEP, TI as well as experimental data, while HNC/HS and PW/HS produce least accurate 
results. Particularly, the energy difference between HNC/HS and experiment is more than 
4 kcal/mol for the case of NMA for all values of cutoffs. LRA/HS also produces 
reasonable results, however, not as good as GF/HS in terms of the solvation free energy 
difference between the two compounds. 
Finally, the approach was tested on some small organic molecules using two 
different force fields GAFF and OPLS, and the results are shown in Tables 3.3 and 3.4, 
respectively. For the OPLS force-field and HF/6-31G(d,p) charges, LRA/HS performs 
much better than HNC/HS, PW/HS, GF/HS and even slightly better than TI in 
comparison with experimental data. For the GAFF force field and the HF/3-21G charges, 
LRA/HS produces reasonable results except for Acetic acid. In general, LRA/HS 
performs better with OPLS than with the GAFF force field in this study. 
 
Table 3.2 Free energies of solvation (kcal/mol) calculated by coupled RISM-HNC/ MD 






























-9.28 -10.4 -11.3 -10.1 





Table 3.3 Free energies of solvation (kcal/mol) calculated by coupled RISM-HNC/ MD 




 GF/HS PW/HS LRA/HS Expt. 
















































































3.1.4 Conclusion and outlook 
The present study shows that applying LRA/HS for solvation free energy 
produces a reasonably accurate prediction in comparison to experiment or other MD 
methods as well as other free energy expressions. Considering the accuracy and 
computational cost, the method is a good tool for solvation free energy calculations. 
However, all molecules used in this study are smaller than a typical drug-like compound. 
Therefore, more testing is needed to see if convergence problems appear as the molecular 
sizes increase before the method can be applied widely for quantitative analysis in 




Table 3.4 Free energies of solvation (kcal/mol) calculated by coupled RISM-HNC/MC 
with the OPLS force field and HF/6-31G(d,p) charges, compared to experimental values 




 GF/HS PW/HS LRA/HS TP* Expt. 













































































-4.84 -4.51 -5.1 




3.2 Explicitly-solvated ligand contribution to continuum  
solvation models for binding free energies:  Selectivity of  
theophylline binding to an RNA aptamer 
3.2.1 Introduction of MM-PB/LRA-SA 
The MM-PBSA method evaluates solvation free energy, by using a dielectric 
continuum model, which represents the solvent implicitly as a continuum environment 
51-
53
. The method has been widely used because it provides adequate accuracy at low 
computational cost. However, in certain biological systems in which solvent plays an 
important role in ligand binding, neglecting explicit solvent interactions might leads to 
unreliable results. To provide more accurate computational estimates of binding free 
  
43 
energies in solution from MD simulations, Freedman et al. proposed to use a separate 
solvation contribution for the binding ligand, determined from a linear response 
treatment. The new approach is called Molecular Mechanics, Poisson Boltzmann, and 
Surface Area contributions (MM-PB/LRA-SA).  
In the approach taken here, the solvation part is decomposed into ligand and 















LRASA  (3.2) 
 
The contribution to the solvation free energy difference upon ligand binding from the 
receptor is calculated by the PBSA (or the GBSA) approximations; ligand contributions 
to solvation free energy are calculated from the LRA expression and summed to the 
receptor contribution to obtain total contributions of solvation to binding free energies. 
LRA solvation free energy components were calculated as averages over values 
determined from radial distribution functions
15



































3.2.2 Using MM-PB/LRA-SA to study selectivity of Theophylline  
binding to an RNA aptamer 
Characteristics of Theophylline to an RNA aptamer. Theophylline and its 
derivatives (shown in Figure 3.1) bound to an RNA aptamer are interesting cases for 
assessment of the MM-PB/LRA-SA method. First, the systems have important 
applications in biomedicine. Second, solvation usually plays an important role in the 
thermodynamics of ligand binding to RNA aptamers due to its highly anionic nature and 
relatively solvent-accessible binding site. Third, a theoretical study of these systems  by 
Gouda et a.l
54
 using the MM-PBSA method has been done. However, this continuum 
model ranked several of the analogues in the wrong order  (theophylline > 1-
methylxanthine > 3-methylxathine > xanthine > caffeine) compared  to experimental 
binding free energies (theophylline > 3-methylxathine > xanthine > 1-methylxanthine > 
caffeine)
55
. The differences in binding free energies of these analogs between MM-PBSA 
and experimental studies are also significant thus make the systems an interesting case 
for assessment of the MM-PB/LRA-SA method. In addition, the systems are also 
interesting cases for studying how interlocking structural motifs can be assembled into a 
highly specific ligand-binding site that has strong affinity and molecular discrimination in 
the RNA aptarmer. The initial structure of the theophylline-bound RNA aptamer used in 
this study (Figure 3.2) was provided by Gouda et al., which was originally derived from 







Figure 3.1 Chemical structures of theophylline (A) and derivatives, 1-methylxanthine 











Figure 3.2 Conformation of theophylline-bound RNA aptamer after MD simulation, with  
triples labeled by residue and distinguished by separate colors, visualized using the 
Pymol viewing program.
56
  Grey balls represent Mg2+ ions. 
 
Relative binding energies of the five analogs from MM-PBSA and MM-PB/LRA-
SA vs. those from experiments are shown in Figure 3.3 A and B, respectively. The 
squared correlation coefficients of the linear fits in the two graphs show that MM-
PB/LRA-SA (0.9966) outperforms MM-PBSA (0.9156). Total Binding Free Energies are 
shown in Table 3.5. MM-PB/LRA-SA calculates the preferential binding order of the five 
ligands in the order, theophylline > 3-methylxathine > 1-methylxanthine > xanthine > 






Figure 3.3 Relative binding free energies calculated by (A) MM-PBSA and (B) MM-
PB/LRA-SA for the 5 theophylline analogues compared with experimental data, showing 





  relative order of xanthine and 1-methylxathine) while MM-PBSA and MM-GBSA 
completely misranked the binding affinities of these compounds. 
Table 3.5 shows relative binding energy of the four analogs compared to 
theophylline.  Compared to experiment and TI, results derived from the LRA-SA method, 
which require an additional simulation, are more reasonable than MMPB-SA or MMGB-
SA alone, both in the values of binding energy and the ranks of all compounds of interest. 
In all methods, there is a significant difference in binding affinity between caffeine and 
theophilline. The reason might be that this compound occupies a different binding site 











Table 3.5 Calculated binding free energies of theophylline and analogues, compared 
between different methods and with experimental values.  Values are given relative to the 





each of complex 
and ligand













































































3-Methylxanthine 3.4 3.0 0.0 0.4 1.100.05 1.361.04 
Xanthine 4.8 5.1 1.3 3.5 1.960.28 1.640.83 
1-Methylxanthine 2.9 2.8 0.4 1.7 1.990.29 1.820.33 
Caffeine 7.0 8.9 5.2 7.7 5.550.02 6.630.82 
‡ ref [55], * ref [54] 
 
3.2.3 Conclusion and outlook 
The MM-PB/LRA-SA method produces quite accurate relative binding free 
energies for 5 theophylline and its four derivatives to the RNA strand with reasonable 
computational cost. In comparison to MM-PBSA alone the MM-PB/LRA-SA method 
requires about twice the computational cost. The method requires running the same 
simulations with all nonbondede interactions of the ligand with the water molecules 
turned off.  Whereas, conventional MD simulation methods (e.g. FEP) would require a 
computing approximately 10 times more than that of MM-PB/LRA-SA considering the 
cost of testing to find suitable restraints to keep ligand binding modes unchanged during 
simulations and both forward and backward simulations for validation. 
  
49 
Theoretically, the approach is straightforward and feasible to be implemented in 
the available MD packages (e.g AMBER or NAMD) and, in our opinion, thus is 
applicable for quantitative analysis in lead optimization. However, the level of accuracy 
achieved in this study may be due to the high similarity in the compounds of interest, 
leading to cancellation of error in calculations.  To apply the method to sets of ligands 














MOLECULAR MODELING OF MUTATION-INDUCED  
OSELTAMIVIR DRUG RESISTANCE FOR 
 INFLUENZA N1 NEURAMINIDASES 
 
In Chapter 4, we discuss our observations, based on drug-protein endpoint 
interactions on how the mutations H274Y and N294S induce oseltamivir resistance in 
neuraminidase N1 subtypes. Part of Chapter 4 originally appeared in PLoS Curr 
Influenza, RRN1015 and in a manuscript submitted to J. Mol. Med. The work was done 
in collaboration with Eric Lee. David Hardy also contributed to the calculations of 
electrostatic surface potential. 
 
 
4.1 Literature review of oseltamivir-resistance and  
our proposed study 
Genetics study of influenza H5N1 virus isolated from patients who died despite 
being given oseltamivir showed that mutations H274Y or N294S confer high-level 
resistance to oseltamivir.
11, 57, 58
  There is even emerging evidence that these drug-
resistant mutants pose the same risk with H1N1pdm, as shown by reported cases of the 
H274Y mutation of H1N1pdm.
59-62
  The rapid emergence of oseltamivir resistance in 
avian flu has already motivated numerous studies, both experimental and theoretical, to 
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uncover the mechanisms of how point mutations in neuraminidase alter drug binding. 
Despite initial inroads, the current understanding of drug resistance remains incomplete 
and some conclusions are conflicting.  For example, in one study, it was reported that the 
H274Y mutation disrupts the E276-R224 salt bridges, but in a separate study the same 
salt bridges were observed to be stable. 
  In this study we characterize the drug-protein interactions of oseltamivir bound 
forms of wild type avian H5N1 and swine H1N1pdm neuraminidases and how their 
mutations, H274Y and N294S, rupture these interactions to confer drug resistance 
through molecular modeling and all-atom molecular dynamics simulations (MD). 
 
4.2 Computational details 
 The coordinates for the H5N1 neuraminidase bound with oseltamivir was taken 
from a monomer of the Protein Data Bank (PDB) structure 2HU4 (tetramer), while those 
of mutants H274Y and N294S were taken from structures 3CL0 (monomer) and 3CL2 
(monomer) respectively.
63
 Even though the biological form of neuraminidase is 
tetrameric, its monomer contains a functionally complete active site and yields reasonable 
results in a prior study using MD simulations.
64
 The position for oseltamivir bound to 
H1N1pdm was adopted from its corresponding location in H5N1, as the two proteins’ 
binding pockets differ only by residue 347 (which is Y in H5N1 and N in H1N1pdm), 
located on a loop at the periphery of the active site. Oseltamivir-mutant complexes of 
H1N1pdm were built by mutating H274Y and N294S of the H1N1pdm wild type model.  
In total, 6 systems were modeled and simulated for oseltamivir bound H5N1, and 
H1N1pdm wild type and H274Y and N294S mutants. Crystallographically resolved 
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water molecules and a structurally relevant calcium ion near the native binding site for 
SA were retained and modeled in all simulated systems.  The protein complexes were 
then solvated in a TIP3P
23
 water box and ionized by NaCl (0.152M) to mimic 
physiological conditions.   
All simulations were performed using NAMD 2.7
65
 and the CHARMM31 force 
field with CMAP correction.
66, 67
  The ionized systems were minimized for 10,000 
integration steps and equilibrated for 20 ns with 1 fs time steps. Following this, a 20 ns 
unconstrained equilibration production run was performed for subsequent trajectory 
analysis, with frames stored after each picosecond (every 1000 time steps).  Constant 
temperature (T = 300 K) was enforced using Langevin dynamics with a damping 
coefficient of 1 ps
−1
.  Constant pressure (p = 1 atm) was enforced using the Nosé-Hoover 
Langevin piston method. Van der Waals interaction cutoff distances were set at 12 Å 
(smooth switching function beginning at 10 Å) and long-range electrostatic forces were 
computed using the particle-mesh Ewald (PME) summation method.  
Analysis included the calculation of an averaged electrostatic potential field over 
all frames of the trajectory using RMSD-aligned structures.  Maps of the electrostatic 
potential field were calculated on a three-dimensional lattice. The long-range 
contributions to the electrostatics were approximated using the multilevel summation 
method (MSM), which uses nested interpolation of the smoothed pairwise interaction 
potential, with computational work that scales linearly with the size of the system. The 
calculation was performed using the molecular visualization program VMD that provides 
a GPU-accelerated version of MSM to produce the electrostatic potential map.
68
 The 
GPU acceleration of MSM provided a significant speedup over conventional electrostatic 
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summation methods such as the Adaptive Poisson Boltzman Solver (APBS), achieving a 
benchmark processing time of 0.2s per frame versus 180 seconds per frame (on a 
conventional CPU) using APBS
69
 for a 35,000 atom system, offering a speedup factor of 
about 900.  The use of GPU acceleration enabled averaging the electrostatic potential 
field over all frames of the simulation trajectories.  Hydrogen bond analysis utilized a 
distance and angle cutoff of  3.5 Å and 60 degrees, respectively.  
 
 
4.3 Results and discussion 
Hydrogen bonds form the primary interactions through which many drugs bind to 
neuraminidases.  While the SA binding sites of H5N1 and H1N1pdm appear to differ 
mainly in the sequence of loop residue 347, it is not well understood whether antiviral 
drugs bind to each protein in the same manner, or if the drug resistant H274Y and N294S 
mutations disrupt critical hydrogen bonds.  To address this question, the hydrogen bonds 
which form between oseltamivir and the residues lining the SA binding pockets of H5N1 
and H1N1pdm were calculated for all simulation trajectories. The drug RMSD (Figure 
4.1) of six simulated systems show that the positions of the drugs remain fairly stable 
within the binding pocket, thereby permitting the characterization of the specific drug-
protein interactions responsible for binding oseltamivir to the neuraminidase active site.  
The results of these calculations are illustrated in Figures 4.2A and  4.3A, which show 
histograms listing hydrogen bond frequency, with schematic views of the specific 
residues involved in drug-protein hydrogen bond pairings in Figures 4.2B to 4.2D for 
simEQ4, and simEQ6, respectively.  In both wild type and mutant simulations, hydrogen 















Figure 4.1 Root mean squared deviation (RMSD) of  WT and mutant avian H5N1 and 
swine H1N1pdm neuraminidases across six 20 ns production simulations (simEQ1 to 
simEQ6). The values reflect the equilibration of each of the neuraminidase systems. 
 
 
D151, R292, and R371. Specifically, R292 and R371 were observed to hydrogen bond 
with oseltamivir’s carboxyl moiety, and E119 and D151 with oseltamivir’s amino group 
(NH3
+
).  The H274Y mutation, however, appeared to disrupt the hydrogen bonding of 
oseltamivir’s acetyl group with R152, an interaction which was seen in the wild type and 
N294S systems for both simEQ1 and simEQ2. 
Prior analyses of crystallographic data alone suggested that Y347 forms a stable 
hydrogen bond with oseltamivir’s carboxyl group and is the source of oseltamivir-






Figure 4.2 Network and occupancy of hydrogen bonds stabilizing oseltamivir in the SA 
binding pocket of wild type and drug-resistant mutant avian H5N1 neuraminidases, in 
simEQ1, simEQ3, and simEQ5.(A) shows histograms of the percent of hydrogen-bond 
occupancies for interactions between oseltamivir and residues E119, D151, R152, R292, 
Y347, and R371 across each simulation run. (B) through (D) are schematic views 
depicting the orientation of protein sidechains which form protein-drug hydrogen bonds. 
Hydrogen bonds in all three simulations were conserved for residues E119, D151, R292, 
and R371. The H274Y mutation was observed to disrupt hydrogen bonding to R152. 
Despite the increased interaction with Y347 in the case of the N294S mutant, the 






Figure 4.3 Network and occupancy of hydrogen bonds stabilizing oseltamivir in the SA 
binding pocket of wild type and drug-resistant mutant avian H1N1pdm neuraminidases, 
in simEQ2, simEQ4, and simEQ6. (A) are histograms of the percent of hydrogen-bond 
occupancies for interactions between oseltamivir and residues E119, D151, R152, R292, 
N347, and R371 across each simulation run. (B) through (D) are schematic views 
depicting the orientation of protein sidechains which form protein-drug hydrogen bonds. 
Hydrogen bonds in all three simulations were conserved for residues E119, D151, R292, 
and R371. The H274Y mutation was observed to disrupt hydrogen bonding to R152. Of 
note, residue 347, which distinguishes the binding pocket of H1N1pdm from H5N1, 





Our MD simulations however, reflect statistics collected from long timescale 
simulations which produce a dynamic picture of molecular interactions in greater detail 
and resolution than can be seen from a static crystal structure.  In our simulations 
oseltamivir’s carboxyl group primarily forms hydrogen bonds with R292 and R371, 
having little involvement with Y347.  In fact, residue Y347 undergoes rotation to interact 
strongly with residue W295.  Therefore, the speculation from previous studies, that the 
N294S mutation in the case of H5N1 actually destabilizes the hydrogen bonding between 
oseltamivir and Y347 to induce drug resistance, is not supported in our simulations.  
The notable difference between H5N1 and H1N1pdm neuraminidases is the 
replacement of Y347 by N347 at the drug binding pocket.
14
 No conserved drug-protein 
hydrogen bond was observed for N347 in any of the three H1N1pdm simulations.  Given 
the transient nature of even the N294S mutant induced hydrogen bond involving residue 
347 in the case of H5N1, and the lack of interaction with residue 347 in any of the other 
simulations, it is highly unlikely that the single residue change (Y347 to N347), between 
the H5N1 and H1N1pdm strains significantly alters the drug-protein stability in regard to 
the hydrogen bond network involved. H274Y mutation induced disruption of the stable 
hydrophobic packing of oseltamivir’s pentyl group in both H5N1 and H1N1pdm 
neuraminidases 
Beyond disrupting the drug-protein hydrogen-bonding network, another 
mechanism through which protein mutations may induce drug resistance is by disruption 
of the hydrophobic packing of the drug into the protein binding pocket.  Through 
inspection of the static crystal structures of the H274Y and N294S mutants of H5N1, it 
has been speculated that the mutations disrupt favorable hydrophobic packing 
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interactions necessary for strong binding of oseltamivir. In our wild type simulations for 
both the H5H1 and H1N1pdm systems, the packing of oseltamivir’s pentyl moiety tended 
to favor close association with residues I222, R224, A246, and E276. To test the effect of 
mutations H274Y and N294S on hydrophobic interactions of oseltamivir’s pentyl group 
with the proteins, we calculated the solvent accessible surface area (SASA) of 
oseltamivir’s pentyl group for all simulation trajectories.  While there was no significant 
change to the pentyl group SASA (henceforth referred to as PG-SASA) in the wild type 
and N294S mutant for either H5N1 or H1N1pdm neuraminidases, an outward rotation of 
the pentyl group was observed in the H274Y mutant simulations, visible in oseltamivir’s 
binding pose and evident in a notably higher calculated PG-SASA.  The PG-SASAs for 
all simulated systems are plotted in Figure 4.4, with inset images of oseltamivir’s binding 
pose in simEQ2 (Figure 4.4A) and simEQ4 (Figure 4.4B) illustrating the rotation of the 
pentyl group towards the open mouth of the binding pocket.   
Previously published MD simulations performed over relatively short time scales (3 to 6 
ns) have suggested two possible mechanisms: 1) that the H247Y mutation reduces the 
size of the hydrophobic pocket within the SA binding pocket near Oseltamivir’s pentyl 
moiety,
70
 and 2) that the H274Y mutation breaks a critical salt bridge between E276 and  
R224 to disrupt drug binding.
71
  Our longer (40ns) simulations were able to corroborate 
the former suggested mechanism (as shown by the increase in PG-SASA in the case of 
the H274Y mutant simulations) but not the latter.  In fact, in all six of our simulations, 
E276 maintains stable charge-charge interactions (salt bridging) with R224 despite 





H274Y mutants.  This drug displacement increases water penetration into the I222-R224- 
A246-E276 pocket (Figure 4.4B).  Evidence from our simulations therefore supports 
predictions from earlier studies of a possible mechanism for the H274Y mutation-induced 
drug resistance through water infiltration and destabilization of favorable drug packing.
72
 
However, because no change in PG-SASA was observed during our simulations in the 
case of N294S for either protein, N294S induced drug resistance is probably due to a 
different mechanism.  
 
Figure 4.4. The solvent accessible surface area of oseltamivir's pentyl group (PG-SASA) 
in H5N1 and H1N1pdm wild type and mutant simulations.The PG-SASA in the N294S 
mutant simulation (simEQ5 and simEQ6) did not vary significantly from wild type 
simulations (simEQ1 and simEQ2). However, there was a huge loss of hydrophobic 
interaction between drug and protein in the case of the H274Y mutant simulations 





While alterations in hydrophobic sidegroup packing may explain in part the 
mechanism behind H274Y mutation-induced drug resistance, they fail to shed light on 
the role that the N294S mutation plays for oseltamivir binding inhibition.  Initial 
investigations of the electrostatic surface potentials of drug-bound N1 neuraminidases  
have proposed that drug binding affinity is closely related to favorable charge-charge 
interactions with the electrostatic potential of the binding pocket wall, which exhibits a 
weak negative charge.
12
  In order to understand whether charge-charge interactions may 
play a role in mutation induced drug resistance, the electrostatic potentials were 
calculated and mapped onto the surfaces of the proteins. 
Even though prior studies have investigated the possible role of the electrostatic 
surface potential for drug binding in neuraminidases, the extensive electrostatic 
calculations required for fully understanding role of this phenomenon over a long 
simulation trajectory has not yet been done. The electrostatic surface potentials of the 
equilibrated systems were calculated and averaged across every trajectory frame in six 
equilibrium simulations described in Table 4.1 using the GPU accelerated multilevel 
summation method (described in the Methods section).
68
 Extensive electrostatic 
calculations for the six systems show that the mouth of the binding pocket is positively 
charged, except for a narrow pathway of negative surface charge that seems to direct a 
possible binding pathway through which the drug may access the binding pocket.  In 
Figure 4.5, the electrostatic surface potentials calculated from all six simulations is shown 




Table 4.1 Summary of simulations. The “ensemble” column lists the variables held 
constant during the simulations; N, p and T correspond to the number of atoms, pressure, 
and temperature, respectively. The simulation times reflect a 20 ns setup/equilibration run  
followed by a 20 ns production run.  
 
Name  Structure Atoms Ensemble Time (ns) 
simEQ1  H5N1 + oseltamivir 34860 NpT 40 
simEQ2 H1N1pdm+ oseltamivir 34707 NpT 40 
simEQ3  H274Y-H5N1 + oseltamivir 34880 NpT 40 
simEQ4 H274Y-H1N1pdm+ oseltamivir 34729 NpT 40 
simEQ5  N294S-H5N1 + oseltamivir 34873 NpT 40 
simEQ6 N294S-H1N1pdm+ oseltamivir 34727 NpT 40 
 
 
snapshots from simEQ1, simEQ3, and simEQ5, respectively, and Figures 4.5D-F 
corresponding to simEQ2, simEQ4, and simEQ6, respectively. 
 
4.4 Conclusion and outlook 
 Mutation H274Y in the H1N1pdm virus shares the same sources of oseltamivir 
resistance as  H5N1, including loss of hydrogen bonds with R152 and reduction of 
hydrophobic interaction of oseltamivir’s pentyl group. This leads to our suggestion to 
replace the pentyl group by a more hydrophilic one by adding a few hydroxyl groups on 
this bulky hydrophobic group. Our results do not support previous suggestions that the 
N294S mutation of H5N1 destabilizes the hydrogen bonding between oseltamivir and 
Y347, or that it disrupts the hydrophobic pocket, leading to drug resistance. Sources of 





Figure 4.5 Electrostatic surface potential of avian H5N1 and swine H1N1pdm 
neuraminidases in oseltamivir-bound simulations, revealing a positively charged pathway 
into the binding pocket. (A) through (C) show oseltamivir bound to H5N1 wild type, 
H274Y, and N294S drug-resistant mutant structures, respectively. (D) through (F) show 
oseltamivir bound to wild type, H274Y, and N294S drug-resistant mutant structures, 
respectively.  The outer columns show a close-up view of the binding pocket, highlighted 
as a subset of the enter protein shown in the central column.  The positions of the mutant 
residues are shown in green for residue 274 and 294 in the mutant systems.   Simulations 
revealed the presence of a negatively charged pathway at the mouth of the binding pocket 
which may play a role for drug binding and mutation induced resistance, as the position 
of residue 294 maps directly onto the pathway while position of residue 274 is positioned  
on or adjacent. 
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WT and the mutants will be importantly complementary to obtained results in this 
chapter. Since the two mutations are nonactive-site, endpoint interactions alone cannot 
account for all drug resistance. Kinetics of drug binding is therefore also important for 
drug resistant mechanism. Especially, based on the decrease in association rate constants 




 in the WT, 0.24 
2.52 μM−1s−1  in H274Y and 1.1 2.52 μM−1s−1  in N294S mutants), we speculate that 
mutations also prevent drugs from entering the SA binding site.  It is hoped that our 
observation of a possible binding pathway for oseltamivir will encourage further 
investigations that test the hypothesis posed here, by identifying whether the actual drug 








AN ELECTROSTATIC FUNNEL DIRECTS BINDING OF  




Chapter 5 is a follow-up study based on the observation in Chapter 4. This chapter 
reflects what was reported in a manuscript submitted to PLoS Computational Biology 
with the same title.
17
 The work was done in collaboration with Eric Lee. Klaus Schulten 
also made a significant contribution in writing the manuscript. 
 
 
5.1 Characteristics of the electrostatic surface potential of N1  
neuraminidases shed light for further study on drug binding  
and drug resistance 
Up to this point, all proposed mechanisms for oseltamivir resistance have focused 
on the effects of the mutations on the SA binding site but little has been known about the  
effects of those mutations on the kinetics of drug binding. Since both H274Y and N294S 
are nonactive site mutations, prior studies which focused on endpoint interactions 
between drug and proteins have been unable to provide a full understanding of how these 
mutations directly impact drug binding. In fact, given that the drug binding kinetics of 
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H5N1 mutants are significantly diminished, it is possible that these mutations alter the 
binding process, and not necessarily just the specific endpoint interactions.  
It is well known that electrostatic surface potential of a protein can be an 
important driving force directing the diffusion of ligands into a protein’s active site.73, 74 
The resulting electrostatic maps shown in Figure 5.1A for H5N1 and  Figure 5.1B for 
H1N1pdm reveal a highly negatively charged column of residues that forms a pathway 
10 Å in length between the SA binding site and the edge of the binding cavity mouth. 
Electrostatic calculations also reveal that oseltamivir has a highly positive electrostatic 
surface potential, illustrated in Figure 5.1C. The question arises whether the negatively 
charged surface column plays a role in the binding and unbinding of oseltamivir, given a 
possible mutual attraction between oseltamivir and this column. To answer this question, 
we employed SMD simulations (described in the Methods section) to pull oseltamivir out 
of the SA binding site and probe possible unbinding pathways. Such simulations have  
  
 
Figure 5.1 Electrostatic surface potential of the SA binding pocket of H1N1pdm and 
oseltamivir. Shown in A) and B) are closeup views of the SA binding pocket with drug 
bound H1N1pdm and avian H5N1 neuraminidase, respectively. The region of the binding 
pocket where the drug bound possesses a highly negative potential (colored red), whereas 
the openingof the pocket is surrounded by a highly positive potential ring (colored blue). 
In C), a detailed surface electrostatic potential for oseltamivir. Shown are the “front” side 
facing the annulus of the binding pocket, and “back” side facing the interior of the 





5.2 Computational details 
A summary of simulations is shown in Table 5.1. In total, 6 systems were 
modeled and simulated for oseltamivir bound H5N1, and H1N1pdm wild type and 
H274Y and N294S mutants. 
In simSMD1, steered molecular dynamics (SMD) simulations were used to 
remove oseltamivir from its stable binding site in H5N1 neuraminidase. In simFEQ1-10, 
equilibration simulations used a starting point generated from simSMD1 in which 
 
Table 5.1 Summary of simulations. The “Structure” column lists the type of 
neuraminidase, associated mutations, and drug modeled in each system. 
 
Name Structure Atoms Type Ensemble Time (ns) 
simSMD1 H5N1 + oseltamivir 34860 SCV NV 15 
simFEQ1 H5N1 + oseltamivir 34860 EQ NpT 15 
simFEQ2 H5N1 + oseltamivir 34860 EQ NpT 10 
simFEQ3 H5N1 + oseltamivir 34860 EQ NpT 15 
simFEQ4 H5N1 + oseltamivir 34860 EQ NpT 50 
simFEQ5 H5N1 + oseltamivir 34860 EQ NpT 100 
simFEQ6 H5N1 + oseltamivir 34860 EQ NpT 10 
simFEQ7 H5N1 + oseltamivir 34860 EQ NpT 15 
simFEQ8 H5N1 + oseltamivir 34860 EQ NpT 50 
simFEQ9 H5N1 + oseltamivir 34860 EQ NpT 50 





oseltamivir has undergone an axial rotation such that it is partially displaced from its 
binding site. In total, 680 ns of simulations were carried out on system sizes of 
approximately 35,000 atoms. 
The “Ensemble” column lists the variables held constant during the simulations; 
N, p, T, and V correspond to the number of atoms, pressure, temperature, and volume 
respectively. Under “Type”, EQ denotes equilibration, and SCV denotes constant 
velocity SMD simulation with the speed of 0.5 Å/ns. SimSMD1 is a steered MD 
simulation with the starting structure from equilibrated simEQ1 (“preflip” drug position). 
In simFEQ1 to simFEQ10, the starting structure reflected a “flipped” position of 
oseltamivir from simSMD1 after 7.5ns of simulation, whereas several of its main 
stabilizing hydrogen bonds to the protein had already been ruptured. Crystallographically 
resolved water molecules and a structurally relevant calcium ion near the native binding 
site for SA were retained and modeled in all simulated systems. The protein complexes 
were then solvated in a TIP3P water box 
23
 and ionized by NaCl (0.152M) to mimic 
physiological conditions. 
All simulations were performed using NAMD 2.7 and the CHARMM31 force 
field with CMAP correction. The ionized systems were minimized for 10,000 integration 
steps and equilibrated for 20 ns with 1 fs time steps. Following this, a 20 ns 
unconstrained equilibration production run was performed for subsequent trajectory 
analysis, with frames stored after each picosecond (every 1000 time steps). Constant 
temperature (T = 300 K) was enforced using Langevin dynamics with a damping 
coefficient of 1 ps−1. Constant pressure (p = 1 atm) was enforced using the Nose´-
Hoover Langevin piston method with a decay period of 100 fs and a damping time 
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constant of 50 fs. Van der Waals interaction cutoff distances were set at 12Å, (smooth 
switching function beginning at 10 Å) and long-range electrostatic forces were computed 
using the particle-mesh Ewald (PME) summation method with a grid size of less than 1Å, 
along with the pencil decomposition protocol where applicable. SMD simulations fixed 
the center of mass of neuraminidase -carbons and applied a force to the center of mass of 
oseltamivir, along a vector connecting the two center of masses. 
In simSMD1, a constant velocity protocol was employed, with stretching velocity 
of 0.5Å/ns. For the SMD spring constant,
78, 79
 we chose kSMD = 3kBT/Å
2
 which 
corresponds to an RMSD value of  (pkBT/kSMD)
1/2
 < 0.6 Å. 
 
5.3 Results 
To simulate the binding of the drug would be the most natural approach, but the 
computations would be rather expensive. Unbinding simulations however are feasible 
and may also reveal features that are characteristic for binding. In simSMD1, a pulling 
force was applied to rupture all the stabilizing hydrogen bonds between H5N1 and 
oseltamivir, in order to draw the drug away from the SA binding site. The results of 
simSMD1 show that the behavior of oseltamivir under effect of a pulling force can be 
divided into three distinct stages: 1) from 0 to 8 ns, a buildup of forces during which 
hydrogen bonds between oseltamivir with E119, D151 and R152 are destabilized; 2) at 8 
ns where the remaining stable hydrogen bonds with R292 and R371 rupture; 3) after 8 ns 
during which the drug is pulled out of the binding pocket. Figure 5.2 shows the force 
dependent rupture of hydrogen bonds in simSMD1 by plotting both hydrogen bond 





Figure 5.2 Distances between hydrogen bond acceptor-donor pairs between oseltamivir 
and active site amino acids vs. simulation time in simSMD1. Most hydrogen bonds were 
quickly broken by the pulling force except for those with R292 and R371, which fully 
ruptured only after 8 ns, corresponding to the peak of the curve of the applied force vs 
simulation time (shown in inset). position of oseltamivir and all its possible hydrogen 
bonding pairs with residues located along this pathway, it was seen that nonspecific 
electrostatic attractions formed the predominant interactions between drug and protein.  
 
 
oseltamivir followed a lateral escape path through strong interaction with the negatively 
charged column of residues indentified via electrostatic mapping above, despite 
application of force to pull the drug straight out of the binding pocket. This divergent 
path taken by the drug is shown in Figure 5.3A-D. A second notable observation in 




Figure 5.3 Forced unbinding of oseltamivir from H5N1 neuraminidase. Shown here are 
the relative positions of oseltamivir on the electrostatic surface of avian H5N1 
neuraminidase during simSMD1.At 0 ns (A), oseltamivir was stably bound within the 
active site, as seen in simEQ1. Application of force ruptured the stabilizing hydrogen 
bonds between H5N1 and oseltamivir (see Figure 5.2), drawing the drug away from its 
stable binding site within 10 ns, as shown in B. Over the next 2.5 ns of pulling, 
oseltamivir followed the charged binding funnel (shown in C) until it was completely free 
of the protein binding pocket after 15 ns, as shown in D).  
 
 
carboxyl functional group and residues R292 and R371 of the binding pocket, the drug 
underwent a rather significant rotation due to the destabilization of hydrogen bonds with  
E119, D151 and R152. It is likely that this rotation or “flip” is crucial for placing 
oseltamivir in a position which permits it to leave the SA binding site. Despite 
application of force to pull oseltamivir straight out of its binding pocket, the drug 
followed a somewhat lateral path through the electrostatically charged funnel. The 
“preflip” or stably bound state for oseltamivir in H5N1 is shown in Figure 5.4A1, 5.4A2, 




Figure 5.4 Oseltamivir in “flipped” position (position of oseltamivir at 7.5ns in 
simSMD1) in comparison with its stable equilibrium position, shown with the 
electrostatic surface potential of the protein. In A1, the stable binding pose of oseltamivir 
is shown prior to application of force in simSMD1, with stable hydrogen bonds to E119, 
D151, R152, R292, and R371 (shown in A2). After 7.5 ns, however, oseltamivir had 
adopted a new binding pose (shown in B1), where hydrogen bonds with E119, D151, and 
R152 were ruptured, leaving only stable interactions with R292 and R371 (shown in B2). 
The blue arrow in A1 denotes orientation change of the drug from “preflip” to “flipped” 
positions, shown in A3 and B3 respectively with contrast position in transparent mode. 
The weakly bound “flipped” position of oseltamivir in B1, B2 and B3 was used as the 
starting point for simulations simFEQ1-10. 
 
It was observed in simSMD1 that following the transition to the flipped state, very 
little force was then required to subsequently draw oseltamivir out of its binding pocket 
in neuramidase. This result suggests that one may be able to probe the unbinding pathway 
via diffusion, if the starting state consists of oseltamivir already in its flipped orientation. 
We therefore performed additional equilibrium simulations (simFEQ1-10) with 
oseltamivir already in this flipped state. From these simulations, we were able to observe 
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two distinct outcomes: 1) oseltamivir is able to escape the binding pocket by interacting 
favorably with the charged binding funnel and 2) the drug returns, not unexpectedly, to 
its stably bound “preflip” state. Each simulation for FEQ1-10 was run long enough to 
observe either outcome, with the exception of FEQ5. SimFEQ5 was a special case in 
which the drug, after following the binding funnel to escape the protein, actually rebound 
to the SA active site through the same binding funnel after we extended the simulation to 
follow its movement. A summary of observed outcomes from these simulations is shown 
in Table 5.2. 
In simFEQ1-5, oseltamivir successfully escaped the SA binding site, whereas in 
simFEQ6-10, oseltamivir returned to its stably bound “preflip” state. Oseltamivir was 
observed to diffuse out of the SA active site after strong interaction with the 
electrostatically charged binding funnel (described above) in five out of ten equilibrium 
 
Table 5.2 Summary of FEQ1-10 simulations starting from “flipped” position of 
oseltamivir taken from simSMD1 at 7.5 ns. 
 
Name Result Time (ns) 
simFEQ1 Drug escape via binding funnel 15 
simFEQ2 Drug escape via binding funnel 10 
simFEQ3 Drug escape via binding funnel 15 
simFEQ4 Drug interaction with binding funnel but escape via 
430-cavity 
50 
simFEQ5 Drug escape and rebind into SA pocket via binding 
funnel 
100 
simFEQ6 Drug returned to “preflip” position 10 
simFEQ7 Drug returned to “preflip” position 15 
simFEQ8 Drug returned to “preflip” position 50 
simFEQ9 Drug returned to “preflip” position 50 





simulations we performed (simFEQ1-5). In four of the cases (simFEQ1-3, 5 ) oseltamivir 
was observed to diffuse along the full length of the binding funnel before disassociating 
with neuraminidase. Snapshots from a representative simulation (in this case simFEQ1) 
illustrating the trajectory oseltamivir follows along our proposed binding funnel are 
shown in Figure 5.5A. This trajectory and those from simFEQ2,3, and 5 can be visualized 
even more clearly in Movies S1, S2, S3, and S5 in Appendix. In simFEQ4, oseltamivir 
was observed to briefly interact with the binding funnel, but diffused out of 
neuraminidase through an alternate path, namely, the “430-cavity” identified in earlier 
computational study.
12
 Specifically, the simulation revealed that hydrogen bonds between 
oseltamivir carboxyl group and the guanidino group of R430 appear to stabilize the 
transition of the drug along this alternate pathway. The 430-cavity is believed to function 
as a secondary binding site for SA, and our simulations here show that it may (not 
surprisingly) also serve as a viable conduit for the binding/unbinding of oseltamivir as 
well. Snapshots from simFEQ4 illustrating the trajectory of oseltamivir through the 430-
cavity are shown in Figure 5.5B, with 430-cavityspecific residues colored in green. In 
simFEQ1-4, once oseltamivir disassociated from neuraminidase, the drug diffused freely 
in the solvent environment away from the protein. However in simFEQ5 we observed not 
only a diffusion of oseltamivir through the charged binding funnel, but also the re-entry 
Snapshots from each of these events in FEQ5 are shown in Figure 5.6. Analysis of 
interactions of the newly rebound oseltamivir with active site residues from 50 to 100 ns 
revealed that the drug was stabilized by hydrogen bonds with Y406, R292, D151, E119, 
and R118, even though the pentyl group had not yet moved to its requisite hydrophobic 
pocket (I222-R224- A246-E276).
81




Figure 5.5 Escape of oseltamivir from H5N1 neuraminidase in equilibrium simulations 
from simFEQ1 and simFEQ4.The initial system for simulation reflected the “flipped” 
orientation of oseltamivir, as illustrated in Figure 4.4. Shown in A) are snapshots from 
simFEQ1, showing the interaction of oseltamivir with H5N1’s electrostatically charged 
binding funnel as the drug diffuses out of the protein’s SA binding pocket. Results were 
similar for simFEQ2-3 and simFEQ5 (see text and Table 5.2 for specific timescale for 
those events), demonstrating a key role for this charged funnel for directing drug 
transition into and out of influenza neuraminidases. In snapshots from simFEQ4, (shown 
in B), oseltamivir briefly interacted with the binding funnel but took a different path out 
of the binding pocket, interacting instead with residues from the so-called “430-cavity”, 
predicted in a prior study
12
 to be a secondary SA binding site. of the drug through the 
same pathway after it had freely diffused away from neuramindase. Specifically, the 
sequence we observed in simFEQ5 was as follows: 1) between 0 to 25 ns oseltamivir 
diffuses out of neuriminidase’s SA active site by following the charged binding  funnel, 
2) between 25 and 35 ns the drug unsuccessfully attempted to rebind from an unsuitable 
direction through hydrogen bond interactions with R152 in the so-called flexible 150-
loop 
80
 ; 3) between 35 and 45 ns, the drug again diffuses away from neuraminidase;  4) 
between 45 and 50 ns, the drug rediscovers the binding funnel, drawing it back into and 






Figure 5.6 Escape and rebinding of oseltamivir through the electrostatic binding funnel 
in H5N1 neuraminidase during simFEQ5.Shown here are snapshots of simFEQ5, in 
which oseltamivir first diffused out of the SA active site through interaction with the 
electrostatic binding funnel (see Figure 5.1) similar to that seen in simFEQ1-3 (see Figure 
5.5A) within the first 25ns of simulation. Between 28 and 35ns, oseltamivir diffuses and 
approaches the periphery of the binding pocket away from the binding funnel, but is 
prohibited from entering due to electrostatic repulsion (45ns). However, between 45 and 
50ns, oseltamivir was observed to approach and enter the neuraminidase binding pocket 
through the binding funnel, adopting a stable position within the SA binding pocket 
through hydrogen bonds with Y406, R292, D151, E119, R118. 
 
Movie S5, illustrating the strongest evidence observed thus far that the electrostatic 
funnel serves a crucial role in both the binding and the unbinding of oseltamivir. 
 
5.4 Discussion and future studies 
Our study has shed light on the important role of the electrostatic surface 
potentials in directing the diffusion of oseltamivir into the SA binding site. From our 
simulations, it is clear that the negatively charged funnel serves as a prominent binding 
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and unbinding pathway for oseltamivir in the wild type systems investigated with SMD 
and followup equilibrium simulations in simSMD1 and simFEQ1-10. It turns out also 
that the binding funnel may possibly play a crucial role in drug resistance caused by 
mutations. The conspicuous location of residue 294, which maps directly onto this 
negatively charged pathway may play a key role in the N294S mutation for disrupting the 
proper guidance of the drug into its binding pocket. Thus, it is possible that the 274 and 
294 mutations may confer drug resistance by not only disrupting the end-point 
interactions of oseltamivir but also its entry into the binding pocket by interfering with 
the binding funnel. While sources of end-point interactions, including hydrogen bonds, 
hydrophobic packing and solvent infiltration, of oseltamivir resistance
70-72
 have been 
thoroughly studied, little is known about the kinetics of the drug binding in mutants at 
atomic level. The idea that drug resistant mutants actually disrupt entry of oseltamivir 
into the SA active site of neurminidase through disruption of an electrostatic binding 
funnel is in part supported by experiments which have noted reduced drug binding 
kinetics in H5N1 H274Y and N294S mutants. Even though the oseltamivir-resistant 
mutations were seen located in or adjacent to the funnel, clearly additional study is still 
needed for a full understanding of how the H274Y and N294S mutations weaken the 
binding of the drug. Furthermore, the mutations might not only affect the electrostatic 
gradient but also the geometry of the drug binding and unbinding path. Future or 
followup studies should therefore focus on the specific drug entry/exit pathways for 
oseltamivir-resistant mutant systems, sampling timescales great enough (such as in the 
case of simFEQ5 described above) to capture both the binding. 
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The role of flexible loop-150 and loop-430 in mediating binding for oseltamivir.  
Previous studies have found that the presence of two flexible loops (termed “150” and 
“430” due to their residue positions) may play a role in guarding drug access to the SA 
binding pocket of N1 neuraminidases.
80
 Our simulations suggest that a loss of hydrogen 
bonds to loop 150 (namely between oseltamivir’s acetyl group and R152) in the H274Y 
mutant systems (simEQ3 and simEQ4). However, based on our simulations, the 
disruption of endpoint interactions between oseltamivir and loop 150 do not appear to 
appreciably destabilize overall drug binding within the primary SA active site. This 
observation, however, does not rule out what role loop 150 (and its associated D151 and 
R152 hydrogen bonds to oseltamivir) or the other flexible loop 430 may play if the drug 
is occupying an observed secondary SA binding site seen in previous studies
12, 82
 and in 
one of our simulation trajectories (simFEQ4). While beyond the scope of this study, it 
remains to be seen therefore, whether these flexible loops are key players involved in 
mutation-induced drug resistance. Our electrostatic maps favor a drug binding/unbinding 
pathway for oseltamivir along the charged binding funnel to the primary SA binding site 
discussed in the results section above, involving possible association with the positions 
occupied by residues 274 and 294. However, simFEQ4 did capture drug unbinding 
through the secondary “430-cavity” binding pocket (via interaction of oseltamivir’s 
carboxyl group and R430’s guanidino group) and subsequently through an alternate 
pathway different from the primary charged binding funnel that we have presented. It is 
possible therefore that because our simulations from which the electrostatic maps were 
derived modeled oseltamivir in its primary binding site, a secondary charged binding 
channel/exit path may emerge when the drug occupies its secondary site; verifying 
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whether such a charged pathway exists would therefore be a suitable endeavor for a 
subsequent studies. 
Our simulations here were restricted to studying six subtypes of N1 
neuraminidase; expanding the scope of investigation to encompass the N2-9 
neuraminidases may potentially reveal similar electrostatic funnels that direct drug 
binding to those proteins. Finally, it is well known that the H274Y and N294S mutants do 
not alter the binding affinity for another antiviral drug, zanamivir,
18
 or certainly not its 
natural substrate, SA. Zanamivir, which shares a higher similarity in structure with SA 
than oseltamivir, might enter SA binding pocket in the same way as the SA but different 
from that of oseltamivir. It is hoped that our observations of a possible charged pathway 
for oseltamivir will encourage further investigations into whether other drug candidates 
follow this route to enter the SA binding site and how they interact with H274Y and 
N294S mutations during the binding/unbinding processes. 
 
5.5 Supplementary information 
Movies located at http://www.ks.uiuc.edu/~lyle/Tamiflu-binding-pathway-
movies.html 
Movie S1. (S1.avi) Trajectory from simSMD1, where a force is applied to 
oseltamivir perpendicular to the plane of the SA binding pocket. Despite the direction of 
force, oseltamivir interacts with and follows the charged electrostatic pathway identified 
and discussed in Figure 5.1, with snapshots shown in Figure 5.3. 
Movies S2-S4. (S2, S3, and S4.avi) Trajectories from simFEQ1-3, respectively, 
for movies S2-S4, showing the diffusion of oseltamivir out of the neuraminidase binding 
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pocket via interaction with the electrostatic binding funnel (see Figure 5.3 for snapshots 
from simFEQ1). 
Movie S5. (S5.avi) Trajectory from simFEQ4, where oseltamivir briefly interacts 
with the electrostatic binding funnel before diffusing out of the neuraminidase binding 
pocket via an alternate pathway in the region of the “430-loop”12 shown in green as 
shown in Figure 5.3. 
Movie S6. (S6.avi) Trajectory from simFEQ5, where oseltamivir diffuses out of 
the neuraminidase active site via interaction with the electrostatic binding funnel, fails to 
enter the active site at a different location at periphery of the binding pocket due to 
electrostatic repulsion, then rebinds stably to neuramindase through entry via the binding 

















This section presents an abstract of published/presented results that are not 
included in this dissertation.  
 
A.1.  A Computational study of mixed aggregates of  
chloromethyllithium with lithium dialkylamides
83
 
DFT calculations were performed to examine the possible formation of mixed 
aggregates between chloromethyllithium carbenoids and lithium dimethylamide 
(LiDMA). In the gas phase mixed aggregates were readily formed and consisted of mixed 
dimers, mixed trimers, and mixed tetramers. THF solvation disfavored the formation of 
















An ion with m/z 143 serves as a biomarker that is often continuously monitored in 
urine samples undergoing screening by electron ionization gas chromatography/mass 
spectrometry (EI GC/MS) for banned anabolic agents. The ion is known to arise from 
trimethylsilyl (TMS)-derivatized synthetic 17-hydroxy, 17-methyl steroids. The purpose 
of this work was to characterize, in detail, the origin(s), structure(s), and mechanism(s) of 
formation of such ions with m/z 143. High resolution mass spectrometry (HRMS) data 
revealed the elemental composition of the D-ring derived m/z 143 ion to be C7H15OSi. 
Analysis of dihydrotestosterone (DHT) and its 2-methyl substituted analog 
dromostanolone by HRMS revealed that an elementally equivalent ion of m/z 143 could 
be derived from the A-ring of TMS-derivatized 3-keto-enol steroids demonstrating that 
an abnormally intense peak in the m/z 143 extracted ion chromatogram of urine samples 
undergoing screening for banned anabolic agents does not necessarily indicate the 
presence of a 17-hydroxy, 17-methyl steroid. To gain information on ion structure, 
breakdown curves for the most abundant product ions of the m/z 143 ion were generated 
using both native and perdeutero-TMS derivatives, providing structures for second, third, 
and fourth generation product ions. An EI-mass spectrum of [16,16,17-
2
H3]-DHT (DHT-
d3) demonstrated that one of the C-16 hydrogen atoms is removed prior to the formation 
of an ion that is highly analogous to the ion with m/z 143 strongly suggesting, in accord 
with all other evidence, one particular fragmentation pathway and resulting product: a 




A.3. Liquid-liquid immiscibility in supercooled aqueous solutions  
driven by water's polyamorphism
85
 
It has long been known that the addition of salts to water favors vitrification. The 
identification of two distinct glass transitions in calorimetric experiments of LiCl-water 
glasses prompted the hypothesis of a liquid-liquid phase separation in supercooled water. 
These experiments, however, could not confirm the existence of two phases, nor their 
composition or dimensions of phase segregation.  
We present direct evidence by computer simulations of the liquid-liquid 
immiscibility that develops in supercooled aqueous solutions. Two water nanophases 
form on hyperquenching of some water solutions: a pure low-density liquid phase that 
vitrifies to LDA, and a higher density water-solute mixture. The immiscibility of 
supercooled aqueous solutions is driven by the transformation of water from a high to a 
low density liquid (LDL): the hydrophilic solutes cannot be incorporated into the 
tetrahedral LDL network and are expelled to form an ion-rich water nanophase. The 
simulation results agree with the interpretation of raman spectra and quantitatively 
reproduce the relative amounts of low and high density water as a function of solute 
content of their experiment. Our simulations yield further insight into the mechanism of 
the process and the dimensions of phase segregation.  
The supercooled solutions are studied through coarse-grained molecular dynamics 
simulations, employing the mW monatomic water model of Molinero et al. The 
formation of ice, that can be controlled by the cooling rate of the solution, is also 
discussed in relation of a minimum LDL cluster size needed to produce ice nucleation in 
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